CLA (conjugated linoleic acid) is a combination of octadecadienoic fatty acid isomers. CLA is popular as a bodybuilding aid and as a dietary supplement for its anti-cancer benefits. However there is no solid proof or recognized mechanism, and only a few studies have been done so far. Despite the various promises made for CLA, a 2004 assessment of the data concluded that while it appeared to help animals, there was a lack of strong evidence of human health benefits.
Similarly, as CLA has no long-term effect on body composition, there is little evidence that it is beneficial for overweight or obese persons. Although CLA improves insulin sensitivity in diabetic rats, there is no proof that it has the same effect in people. According to another study, Conjugated linoleic acid intake lowers the risk of breast or colon cancer. Reduced milk consumption also causes a lower risk of breast or colon cancer.
A range of natural fatty acids are beneficial in health promotion, according to numerous lines of research. Conjugated linoleic acid (CLA)—a name that refers to a combination of positional and geometric isomers of linoleic acid (LA, cis-9, cis-12-octadecadienoic acid). It is one of these fatty acids that is now being studied extensively owing to its health-promoting potential. CLA’s anticancer action is particularly interesting since it inhibits multistage carcinogenesis at relatively low dietary doses. CLA helps to prevent the development of multistage carcinogenesis at various locations in several investigations utilizing in vivo and in vitro models.
CLA, especially the cis 9-trans 11 and trans 10-cis 12 conjugated linoleic acid isomers, helps to suppress the initiation and promotion stages of carcinogenesis. That too, in both in vitro cell and in vivo animal models. Implying that CLA has garnered a lot of attention as a chemopreventive drug. The biological activities and various pathways of CLA in obesity-related malignancies in this study, includes cell lines, animal models, and clinical findings. Diet is a risk factor for the development of prostate cancer. Some dietary components, notably fatty acids, have been linked to cancer promotion. Whereas others have been shown to inhibit tumour growth. Identifying these final variables might thus be a non-invasive method for reducing the prevalence and severity of this illness. As well as an effective adjuvant therapy, particularly in hormone-refractory disease.
CLA (conjugated linoleic acid) is a dietary fatty acid mostly in bovine foods which has anti-mutagenic and anticarcinogenic effects. CLA refers to a series of positional and geometric isomers of linoleic acid, an omega-6 essential fatty acid (LA). conjugated linoleic acid, unlike its parent LA, which encourages tumour growth, it is an effective inhibitor of several human malignancies, including prostate cancer, in animal models and cells. The biological mechanisms by which CLAs elicit these anticancer effects are, however, unknown at this time.
CLA might be a new dietary supplement for people at risk of prostate cancer. Or for those who are having treatment for prostate cancer. Due to its tumorigenesis inhibitory properties. The research on conjugated linoleic acid and prostate cancer is yet to improve. A deeper knowledge of CLA preparations and their constituent isomers’ anticarcinogenic effects in prostate cancer might lead to innovative nutritional management and adjuvant therapy in this illness.